ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Advanced Search Results

  • Title
    ---
  • Authors and Affiliations
    andrea fava
  • 1
  • 2
  • 3
  • Next Page »
Search Again »
  • Abstract Number: 0655 • ACR Convergence 2022

    Proteomic Analysis of Histological Lesions Lupus Nephritis Identifies an Inflammatory Signature of Fibrous Crescents

    Alessandra Ida Celia1, Jeffery Hodgin2, Avi Rosenberg3, Laurence S Magder4, Jill Buyon5, Betty Diamond6, Judith James7, William Apruzzese8, Paride Fenaroli9, Derek Fine1, Jose Monroy-Trujillo1, Mohamed G. Atta1, Peter izmirly10, Michael Belmont5, Anne Davidson6, Daniel W. Goldman11, the Accelerating Medicines Partnership (AMP) RA/SLE12, Michelle Petri11 and Andrea Fava1, 1Johns Hopkins University, Baltimore, MD, 2University of Michigan, Ann Arbor, MI, 3Johns Hopkins University, Ballwin, MO, 4University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD, 5NYU Grossman School of Medicine, New York, NY, 6Feinstein Institutes for Medical Research, Manhasset, NY, 7Oklahoma Medical Research Foundation, Oklahoma City, OK, 8Brigham and Women's Hospital, Boston, MA, 9Università degli Studi di Parma, Parma, Emilia-Romagna, Italy, 10NYU Long Island School of Medicine, New York, NY, 11Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 12Multiple Insitutions

    Background/Purpose: We employed urine proteomics to define the molecular signatures associated with the histological features quantified by the NIH activity and chronicity indices. Methods: Glomerular…
  • Abstract Number: 0994 • ACR Convergence 2022

    Effect of Immunosuppression on COVID Vaccination in Systemic Lupus Erythematosus

    Michelle Petri1, Daniel Joyce2, Kristin Haag2, Andrea Fava3, Daniel W. Goldman1, Diana Zhong2, Shaoming Xiao4, Aaron M. Milstone2 and Laurence S Magder5, 1Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3Johns Hopkins University, Baltimore, MD, 4Johns Hopkins School of Public Health, Baltimore, MD, 5University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD

    Background/Purpose: The risk of COVID-19 infection is increased in patients with systemic lupus erythematosus (SLE), and immunosuppressive medications including corticosteroids impact the risk. Furthermore, immunosuppressive…
  • Abstract Number: 2073 • ACR Convergence 2022

    The Incidence of COVID-19 Infection in an SLE Cohort, and Its Association with Immunosuppressants, SLE Disease Activity, Vaccination Status, and COVID-19 Antibodies

    Laurence S Magder1, Andrea Fava2, Daniel W. Goldman3 and Michelle Petri3, 1University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD, 2Johns Hopkins University, Baltimore, MD, 3Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD

    Background/Purpose: An important clinical question is whether treatments (e.g, corticosteroids, immunosuppressants) or SLE disease activity are associated with an increased risk of COVID-19 infection among…
  • Abstract Number: 0333 • ACR Convergence 2022

    Autoantibody Trajectories Associate with Classification and Treatment Response in Lupus Nephritis

    Andrea Fava1, Carla J. Guthridge2, Joseph Kheir2, Catriona Wagner3, Michelle Petri4, Jill Buyon5, Betty Diamond6, the Accelerating Medicines Partnership (AMP) RA/SLE7, Joel Guthridge2 and Judith James2, 1Johns Hopkins University, Baltimore, MD, 2Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Oklahoma Medical Research Foundation, Oklahoma, 4Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 5NYU Grossman School of Medicine, New York, NY, 6Feinstein Institutes for Medical Research, Manhasset, NY, 7Multiple Insitutions

    Background/Purpose: Autoantibodies are a hallmark of lupus nephritis (LN). While there is known heterogeneity in autoantibody expression among LN patients, the association of autoantibodies with…
  • Abstract Number: 0352 • ACR Convergence 2022

    The Effect of Belimumab (BEL) on Kidney Outcomes in SLE: Results of a Large Integrated Analysis

    Maria Dall'Era1, Andrea Fava2, Christine Henning3, Angela R Jones-Leone4, Angela S Carroll5, Julia H N Harris6, Anne E Hammer7, Roger A Levy4, Laurence S Magder8 and Michelle Petri2, 1University of California, Division of Rheumatology, San Francisco, CA, 2Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 3GlaxoSmithKline, Global Medical Affairs, Durham, NC, 4GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, 5GlaxoSmithKline, US Medical Affairs, Research Triangle Park, NC, 6GlaxoSmithKline, Immunology Biostatistics, Brentford, United Kingdom, 7GlaxoSmithKline, Immunology Biostatistics, Collegeville, PA, 8University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD

    Background/Purpose: BEL, an approved SLE treatment,1 improved kidney outcomes in initial Phase 3 SLE trials.2,3 This post hoc analysis evaluates the effect of BEL on…
  • Abstract Number: 0536 • ACR Convergence 2022

    Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria

    Andrea Fava1, Laurence S Magder2, Daniel W. Goldman3, Jill Buyon4, Betty Diamond5, Joel Guthridge6, William Apruzzese7, Derek Fine1, Jose Monroy-Trujillo1, Mohamed G. Atta1, Peter Izmirly4, H Michael Belmont8, Anne Davidson5, Maria Dall'Era9, Deepak Rao7, Arnon Arazi10, Nir Hacohen11, Soumya Raychaudhuri7, the Accelerating Medicines Partnership (AMP) RA/SLE12 and Michelle Petri3, 1Johns Hopkins University, Baltimore, MD, 2University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD, 3Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 4NYU Grossman School of Medicine, New York, NY, 5Feinstein Institutes for Medical Research, Manhasset, NY, 6Oklahoma Medical Research Foundation, Oklahoma City, OK, 7Brigham and Women's Hospital, Boston, MA, 8NYU School of Medicine, New York, NY, 9University of California, San Francisco, San Francisco, 10Feinstein Institutes for Medical Research, Melrose, MA, 11Broad Institute, Cambridge, MA, 12Multiple Insitutions

    Background/Purpose: A decline of urine protein-to-creatinine ratio (UPCR) to < 0.5 is associated with better long-term preservation of kidney function in lupus nephritis (LN). UPCR…
  • Abstract Number: 0636 • ACR Convergence 2022

    Serum Soluble Mediator Signatures of Lupus Nephritis Histological Features and Response to Treatment

    Andrea Fava1, Carla J. Guthridge2, Joseph Kheir2, Catriona Wagner3, Michelle Petri4, Jill Buyon5, Betty Diamond6, the Accelerating Medicines Partnership (AMP) RA/SLE7, Joel Guthridge2 and Judith James2, 1Johns Hopkins University, Baltimore, MD, 2Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Oklahoma Medical Research Foundation, Oklahoma, 4Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 5NYU Grossman School of Medicine, New York, NY, 6Feinstein Institutes for Medical Research, Manhasset, NY, 7Multiple Insitutions

    Background/Purpose: There is a pressing need to identify novel therapeutic approaches and noninvasive biomarkers in lupus nephritis (LN). In this study, we quantified serum soluble…
  • Abstract Number: 0640 • ACR Convergence 2022

    Immune Cell Heterogeneity in Lupus Nephritis Kidneys and Its Relation to Histopathological Features

    Arnon Arazi1, Joseph Mears2, Thomas Eisenhaure3, Qian Xiao4, Paul Hoover4, Deepak Rao4, Celine Berthier5, Andrea Fava6, Siddarth Gurajala4, Michael Peters3, Tony Jones3, William Apruzzese4, Jennifer Barnas7, Richard Furie8, Anne Davidson9, David Hildeman10, Judith James11, Joel Guthridge11, Maria Dall'Era12, David Wofsy13, Peter Izmirly14, H Michael Belmont15, Robert Clancy14, Diane Kamen16, Chaim Putterman17, Thomas Tuschl18, Maureen McMahon19, Jennifer Grossman19, Kenneth Kalunian20, Michael Weisman21, Matthias Kretzler5, Michael Brenner22, Jennifer Anolik23, Michelle Petri24, Jill Buyon14, Soumya Raychaudhuri4, Nir Hacohen3, Betty Diamond9 and the Accelerating Medicines Partnership RA/SLE Network3, 1Feinstein Institutes for Medical Research, Melrose, MA, 2Michigan University, Ann Arbor, MI, 3Broad Institute, Cambridge, MA, 4Brigham and Women's Hospital, Boston, MA, 5University of Michigan, Ann Arbor, MI, 6Johns Hopkins University, Baltimore, MD, 7University of Rochester, Rochester, NY, 8Northwell Health, Great Neck, NY, 9Feinstein Institutes for Medical Research, Manhasset, NY, 10Cincinnati Children's Hospital, Cincinnati, OH, 11Oklahoma Medical Research Foundation, Oklahoma City, OK, 12University of California, Division of Rheumatology, San Francisco, CA, 13University of California San Francisco, SF, CA, 14NYU Grossman School of Medicine, New York, NY, 15NYU School of Medicine, New York, NY, 16Medical University of South Carolina, Charleston, SC, 17Albert Einstein College of Medicine, Bronx, NY, 18Rockefeller University, New York, NY, 19University of California Los Angeles, Los Angeles, CA, 20University of California San Diego, La Jolla, CA, 21Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, 22Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 23University of Rochester Medical Center, Rochester, NY, 24Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD

    Background/Purpose: Lupus nephritis (LN) is characterized by considerable variability in its clinical manifestations and histopathological findings. Understanding the cellular and molecular mechanisms underlying this heterogeneity…
  • Abstract Number: 0096 • ACR Convergence 2021

    The True Prevalence of SARS-CoV-2 Infection in an Italian Cohort of Patients with Inflammatory Arthritis: A Seroepidemiological Study

    Gabriella Maioli1, Ennio Giulio Favalli2, Elisa Pesce3, Martina Biggioggero2, Mauro Bombaci3, Elena Agape2, Martina Martinovic3, Tanya Fabbris3, Elena Zagato3, Andrea Favalli3, Andrea Gobbini3, Sergio Abrignani3, Renata Grifantini3 and Roberto Caporali4, 1Università degli Studi di Milano, Department of Clinical Sciences and Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Milan, Italy, Milan, Italy, 2ASST Gaetano Pini-CTO Institute, Division of Clinical Rheumatology, Milan, Italy, Milan, Italy, 3Istituto Nazionale Genetica Molecolare, Padiglione Romeo ed Enrica Invernizzi, Milan, Italy, 4Policlinico S. Matteo University, Pavia, Italy

    Background/Purpose: Observational data have shown that rheumatic patients seem not to be more susceptible to SARS-CoV-2 infection neither to worse outcomes. However, the true prevalence…
  • Abstract Number: 0327 • ACR Convergence 2021

    Lipoprotein(a) in Systemic Lupus Erythematosus Is Associated with History of Proteinuria and Renal Insufficiency

    Caoilfhionn Connolly1, Jessica Li2, Daniel Goldman3, Andrea Fava2, Laurence Magder4 and Michelle Petri3, 1Johns Hopkins, Baltimore, MD, 2Johns Hopkins University, Baltimore, MD, 3Johns Hopkins University School of Medicine, Baltimore, MD, 4University of Maryland, Baltimore, Baltimore, MD

    Background/Purpose: Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease. Cardiovascular disease is one of the leading causes of death in patients…
  • Abstract Number: 1284 • ACR Convergence 2021

    One Third of Lupus Nephritis Patients Classified as Complete Responders Continue to Accrue Progressive Renal Damage Despite Resolution of Proteinuria

    Emma Weeding1, Andrea Fava2, Daniel Goldman3 and Michelle Petri3, 1Johns Hopkins Hospital, Baltimore, MD, 2Johns Hopkins University, Baltimore, MD, 3Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Up to 40% of individuals with lupus nephritis (LN) develop chronic kidney disease (CKD). Biopsy studies have revealed that patients with SLE can have…
  • Abstract Number: 1289 • ACR Convergence 2021

    Patients Enrolled in the Accelerating Medicines Partnership (AMP) RA/SLE Network with Isolated Renal Disease Report Minimal Quality of Life Impairment on PROMIS-29 Compared to Patients with Extrarenal Symptoms

    Philip Carlucci1, Jessica Li2, Heather Gold3, Kristina Deonaraine1, Andrea Fava2, Jill Buyon4, Judith James5, Chaim Putterman6, Deepak Rao7, Betty Diamond8, Derek Fine2, Jose Monroy-Trujillo2, Kristin Haag9, Accelerating Medicines Partership (AMP) RA/SLE Network10, H. Michael Belmont4, Sean Connery11, Fernanda Payan-Schober12, Richard Furie13, Celine Berthier14, Maria Dall'Era15, Kerry Cho16, Diane Kamen17, Kenneth Kalunian18, The Accelerating Medicines Parternship In SLE Network19, Peter Izmirly1 and Michelle Petri20, 1New York University School of Medicine, New York, NY, 2Johns Hopkins University, Baltimore, MD, 3NYU Grossman School of Medicine, New York, NY, 4NYU School of Medicine, New York, NY, 5Oklahoma Medical Research Foundation, Oklahoma City, OK, 6Albert Einstein College of Medicine, Bronx, NY, 7Brigham and Women's Hospital, Boston, MA, 8Northwell Health, Manhasset, NY, 9Johns Hopkins School of Medicine, Baltimore, MD, 10Brigham and Women's Hospital, Everett, MA, 11Texas Tech University Health Sciences Center, Texas, TX, 12Texas Tech University Health Sciences Center, El Paso, TX, 13Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 14University of Michigan, Ann Arbor, MI, 15University of California San Francisco, Corte Madera, CA, 16University of California San Francisco, San Francisco, CA, 17Medical University of South Carolina, Charleston, SC, 18UC San Diego, La Jolla, CA, 19Multiple Institutions, Multiple Cities, 20Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Lupus nephritis can occur as an isolated component of disease activity or be accompanied by diverse extrarenal symptoms that can adversely affect a patient’s…
  • Abstract Number: 1299 • ACR Convergence 2021

    Longitudinal Patterns of Response to Standard of Care Therapy for Lupus Nephritis: Data from the Accelerating Medicines Partnership Lupus Network

    Peter Izmirly1, Maria Dall'Era2, Kenneth Kalunian3, Kristina Deonaraine1, Mimi Kim4, Philip Carlucci1, Jessica Li5, Andrea Fava5, H. Michael Belmont6, Chaim Putterman7, Jennifer Anolik8, Betty Diamond9, David Wofsy10, Diane Kamen11, Judith James12, Accelerating Medicines Partership (AMP) RA/SLE Network13, Deepak Rao14, The Accelerating Medicines Partnership in SLE Network15, Michelle Petri16, Jill Buyon6 and Richard Furie17, 1New York University School of Medicine, New York, NY, 2University of California San Francisco, Corte Madera, CA, 3UC San Diego, La Jolla, CA, 4Albert Einstein College of Medicine, Larchmont, NY, 5Johns Hopkins University, Baltimore, MD, 6NYU School of Medicine, New York, NY, 7Albert Einstein College of Medicine, Bronx, NY, 8University of Rochester Medical Center, Rochester, NY, 9Northwell Health, Manhasset, NY, 10University of California San Francisco, San Francisco, CA, 11Medical University of South Carolina, Charleston, SC, 12Oklahoma Medical Research Foundation, Oklahoma City, OK, 13Brigham and Women's Hospital, Everett, MA, 14Brigham and Women's Hospital, Boston, MA, 15Multiple Institutions, Multiple Cities, 16Johns Hopkins University School of Medicine, Baltimore, MD, 17Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY

    Background/Purpose: The Accelerating Medicines Partnership (AMP) Lupus Network was established with the goal of applying novel technologies to the interrogation of blood and tissue samples…
  • Abstract Number: 1422 • ACR Convergence 2021

    Urinary CD163 Predicts Proliferative Lupus Nephritis in SLE Patients with Proteinuria: A Practical Liquid Biopsy Approach

    Andrea Fava1, Jessica Li1, Daniel Goldman2, Jose Monroy-Trujillo1, Mohamed G. Atta1, Derek Fine1, Jill Buyon3, Joel Guthridge4, Judith James4, Michelle Petri2 and Accelerating Medicines Partership (AMP) RA/SLE Network5, 1Johns Hopkins University, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3NYU School of Medicine, New York, NY, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Brigham and Women's Hospital, Everett, MA

    Background/Purpose: Diagnosis of lupus nephritis (LN) relies on a kidney biopsy obtained in SLE with proteinuria. Delayed access to kidney biopsies may delay diagnosis and…
  • Abstract Number: 1436 • ACR Convergence 2021

    Expanded PD-1hi CXCR5- HLA-DR+ T Cells Is Associated with Interstitial Lung Disease in Systemic Sclerosis

    Mehreen Elahee1, Alisa Mueller2, Runci Wang3, Ye Cao2, Andrea Fava4, Paul Dellaripa2, Francesco Boin5 and Deepak Rao2, 1Brigham and Women's Hospital, Natick, MA, 2Brigham and Women's Hospital, Boston, MA, 3Brigham and Women’s Hospital, Boston, MA, 4Johns Hopkins University, Baltimore, MD, 5Cedars-Sinai Medical Center, West Hollywood, CA

    Background/Purpose: Interstitial lung disease (ILD) is the major cause of morbidity and mortality in systemic sclerosis (SSc), yet there are few biomarkers to identify pathologic…
  • 1
  • 2
  • 3
  • Next Page »
Search Again »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences